p28GANK associates with p300 to attenuate the acetylation of RelA

Oncoprotein p28GANK, overexpressed in hepatocellular carcinomas (HCC), binds to RelA and retains NF‐κB in the cytoplasm to suppress NF‐κB transactivation. However, the mechanism has not yet been elucidated. In this study, we clarified the mechanism of NF‐κB regulated by p28GANK. p28GANK reduced TNF‐...

Full description

Saved in:
Bibliographic Details
Published in:Molecular carcinogenesis 2015-12, Vol.54 (12), p.1626-1635
Main Authors: Ren, Y.B., Luo, T., Li, J., Fu, J., Wang, Q., Cao, G.W., Chen, Y., Wang, H.Y.
Format: Article
Language:English
Subjects:
Cellular biology
Chemotherapy
Drug resistance
hepatocellular carcinoma
Liver cancer
NF‐κB
Oncology
p28GANK
p65
Proteins
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Oncoprotein p28GANK, overexpressed in hepatocellular carcinomas (HCC), binds to RelA and retains NF‐κB in the cytoplasm to suppress NF‐κB transactivation. However, the mechanism has not yet been elucidated. In this study, we clarified the mechanism of NF‐κB regulated by p28GANK. p28GANK reduced TNF‐α‐induced nuclear translocation of RelA/NF‐κB independent of HDAC3. p28GANK interacted with p300 to attenuate assembly of RelA with p300, which lessened acetylation of RelA on the lysine 310 sites. Moreover, overexpression of p28GANK attenuated the capability of NF‐κB binding to the target gene IκBα promoter, but also weakened adriamycin‐induced NF‐κB pro‐apoptotic gene Fas and FasL expression, which subsequently made p53‐deficient tumor cells resistance to adriamycin. These results present mechanistic insight into the key role of p28GANK in post‐translational regulation of RelA/NF‐κB. © 2014 Wiley Periodicals, Inc.
ISSN:0899-1987
1098-2744
DOI:10.1002/mc.22235